Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03362190 · ClinicalTrials.gov registry record · Phase 2
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
A Phase 2 study, sponsored by Ophthotech Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT03362190: Completed Phase 2 study, sponsored by Ophthotech Corporation.
NCT03362190 is a Phase 2 study that has completed, run by Ophthotech Corporation. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03362190, a Phase 2 study, has completed, sponsored by Ophthotech Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)
Interventions
- DRUG Lucentis
- DRUG Avacincaptad Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2018-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03362190
The ClinicalTrials.gov registry entry for NCT03362190 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthotech Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lucentis is the first listed.
NCT03362190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03362190 about?
NCT03362190 is a clinical study titled "ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)". To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)
What is the current status of trial NCT03362190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2017-10-11. Estimated completion is 2018-10-18.
What interventions are being tested in trial NCT03362190?
The interventions under investigation include: Lucentis (DRUG), Avacincaptad Pegol (DRUG).
Who is sponsoring clinical trial NCT03362190?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.